32 results about "Clot lysis" patented technology

Clot disruption and dissolution are achieved using a catheter having both an agitator and the ability to deliver a thrombolytic agent. The catheter is introduced to a target region with a blood vessel and the agitator manipulated to engage and disrupt a region of clot therein. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.

An apparatus and method for using ultrasound augmented with microbubbles, thrombolytic drugs or other agents for clot lysis wherein at least one ultrasound transducer generates a plurality of acoustic signals and time, amplitude, phase and frequency modulation of the signals provide more uniform power delivery with fewer gaps in the ultrasound field. Interference patterns from one or multiple transducers are constantly shifted in position. A phased array of transducers may generate a beam that is swept over the area to be treated. In another embodiment, an array of transducers may generate ultrasound at a number of slightly varying frequencies to produce an interference pattern that sweeps in and out through the targeted tissue. A single array may be used to produce both effects simultaneously or separately.

Methods for processing tissues to render them suitable for implantation, e.g. in an orthopedic site. Tissues are rendered substantially acellular and substantially nonimmunogenic by exposure to processes that result in cell lysis, increasing permeability of the extracellular matrix, degrading the debris from lysis, and removing the debris. Methods of forming tissue implants, kits for processing tissue implants, and methods of using tissue implants are also disclosed.

The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; enhancement of hemostasis; increase in clot lysis time; increase in clot strength; and/or increase in overall clot quality (OCQ) in said patient.

The invention relates to immunoconjugates of formula: A-B-(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells, B comprises at least one molecule to which "A" and "C" bind, such as an avidin/strepavidin complex, "C" is an MHC molecule, and "n" is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.

The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein, with or without being in complex with a serpin, comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.

A method for visualizing a blood clot or plaque disposed within a body lumen comprising: binding a contrasting complex comprising a contrast material and a thrombolytic material or a clot dissolving agent to the blood clot or plaque; and visualizing the blood clot or plaque over a period time by a visualizing system.

A therapeutic ultrasound system transmits a staggered or interleaved pattern of therapy beams for use in sonothrombolysis and other Vascular Acoustic Resonators (VAR) mediated therapy. The inventive technique minimizes VAR, e.g. microbubble, destruction due to adjacent beams, ensures uniform sonication of the targeted region by filling in the spaces between the beams in subsequent passes, and further provides a means for bubble replenishment to maximize the clot lysis from ultrasound. The technique is also applicable to diagnostic ultrasound, VAR mediated drug delivery and blood brain barrieropening.

The invention provides a cervical cell lysis kit and a cell lysis method, belonging to the technical field of cell lysis. The kit includes a lysis buffer and proteinase K. The lysis buffer comprises the following components in concentration: 10-500mM of Tris-HCl, 1-80 mM of EDTA, 0.05-2 wt% of SDS and 100-250 mM of NaCl. The cell lysis method comprises the following steps: after cleaning a cervical cell sample solution with PBS buffer, uniformly mixing the solution with lysis buffer, adding proteinase K, and digesting at 53-58 DEG C for 10-14 hours; After 30-60 s of vortex vibration, digestingthe cells at 53-58 DEG C for 1.5-2.5 h to complete cell lysis. The kit and the lysis method can fully lyse cervical cells in the sample, dissociate high-concentration and high-quality DNA, and facilitate subsequent DNA extraction and amplification.

A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed.

A sample testing cartridge is usable to perform a variety of tests on a visco-elastic sample, such hemostasis testing on a whole blood or blood component sample. The cartridge includes a sample processing portion that is in fluid communication with a sample retention structure. A suspension, such as a beam, arm, cantilever or similar structure supports or suspends the sample retention portion relative to the sample processing portion in a unitary structure. In this manner, the sample retention portion may be placed into dynamic excitation responsive to excitation of the cartridge and correspondingly dynamic, resonant excitation of the sample contained within the sample retention portion, while the sample processing portion remains fixed. Observation of the excited sample yields data indicative of hemostasis. The data may correspond to hemostasis parameters such as time to initial clot formation, rate of clot formation, maximum clot strength and degree of clot lysis.

The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to alpha2-antiplasmin crosslinked to fibrin (alpha2AP-FX) which does not inhibit plasma alpha2-antiplasmin (alpha2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward alpha2-antiplasmin crosslinked to fibrin which does not inhibit plasma alpha2AP together with a thrombolytic agent.

A method for amplification of a target DNA, comprising the steps of (i) transferring a liquid with a first volume comprising at least one or more living cells into a vessel (ii) adding to said vessel a PCR reaction buffer with a second volume, whereas said second volume is at least 2× as large as said first volume (iii) lysing said at least one or more living cells within said vessel by means of incubation for at least 1 Minute at at least 90° C., and (iv) amplifying said target by means of a polymerase chain reaction without performance of an intermediate purification step.

The invention discloses a multifunctional intracerebral hematoma drainage tube with multiple secondary tubes, and relates to the technical field of medical apparatus and instruments. The multifunctional intracerebral hematoma drainage tube has the advantages that the multiple secondary tubes are arranged in a header tube, secondary tube extension and retraction holes are formed in the front of theheader tube, and accordingly the secondary tubes can extend out of the header tube or can be retracted into the header tube; medicines can be administrated for multiple points when the fronts of thesecondary tubes extend out of the header tube, drainage can be implemented for the multiple points when the fronts of the secondary tubes extend out of the header tube, the header tube can rotate by 360-degree angles when the fronts of the secondary tubes are retracted into the header tube, the medicines further can be rotationally administrated at 360-degree angles by the multiple secondary tubesat different levels, the purposes of uniformly administrating the medicines for the multiple points on 360-degree circumferences and carrying out drainage for the multiple points on the 360-degree circumferences can be achieved, accordingly, the blood clot lysis and drainage speeds can be increased, compression of hematomas on main functional structures can be quickly relieved, and harm due to hypertensive cerebral hemorrhage diseases can be reduced.

The present invention relates to the use of coagulation proteins for the lysis of blood clots. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.